Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SPECC1
REST API REST API
Homo sapiens
SPECC1 is differentially expressed in 196 experiments: 113 organism parts: bone marrow, cervix, ... (111 more);, 93 disease states: normal, control, ... (91 more);, 68 cell types 304 cell lines 31 compound treatments and 56 other conditions.
Synonyms NSP, HCMOGT-1, FLJ36955, CYTSB
Orthologs Specc1 (Mus musculus)   Cytsb (Rattus norvegicus)   SPECC1 (Bos taurus)   SPECC1 (Gallus gallus)   specc1 (Danio rerio)   CG13366 (Drosophila melanogaster)   cytsb (Xenopus laevis)   SPECC1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, nucleus
InterPro Term CH-domain, CAMSAP_CH
UniProt Accession A8MV89, C9JLR6, Q5M775, B4DQ24, F5H2Z1
Search EB-eye ENSG00000128487
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-803, E-GEOD-6573, E-TABM-130, E-GEOD-26672, ... (16 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-22152, E-GEOD-22560, E-GEOD-14464, E-GEOD-19639, ... (24 experiments)

Factor Value U/D Experiments
SNU1
2
E-MTAB-37, E-GEOD-15460
DU145
2
E-GEOD-17482, E-GEOD-20089
HepG2
2
E-GEOD-21154, E-MTAB-37
MCF-7
2
E-GEOD-19639, E-GEOD-20081
PC3
2
E-GEOD-14464, E-MEXP-2034
KatoIII
1
E-GEOD-15460
298 more value(s).


Cell type

studied in E-MEXP-1242, E-GEOD-22529, E-GEOD-20193, E-GEOD-21668, E-GEOD-20677, ... (35 experiments)

Factor Value U/D Experiments
human embryonic stem cell
2
E-GEOD-18265, E-GEOD-20033
human foreskin fibroblast
2
E-GEOD-18147, E-GEOD-18265
mononuclear
2
E-GEOD-13987, E-GEOD-26672
stromal cell
2
E-MEXP-2034, E-GEOD-1460
HLA-DR negative T-cell
1
E-GEOD-6338
LCC
1
E-GEOD-19188
62 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1922, E-GEOD-6872, E-GEOD-22529, E-GEOD-2508, ... (39 experiments)

Factor Value U/D Experiments
Kaposi's sarcoma
1
E-MEXP-561
plasma cell myeloma
1
E-MTAB-37
ovarian carcinoma
1
E-MTAB-37
uterine fibroid
1
E-GEOD-7307
invasive ductal carcinoma
1
E-GEOD-8977
no atrial fibrillation
1
E-GEOD-2240
87 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5741, E-GEOD-15205, E-TABM-782, E-TABM-868, ... (20 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
M-CSF
1
E-GEOD-5099
PGE2
1
E-MEXP-1230
estradiol
1
E-GEOD-20081
interleukin-4 (Homo sapiens)
1
E-GEOD-5099
mannitol
1
E-GEOD-6400
25 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
34
2
1
E-GEOD-3494


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19246, E-GEOD-4619, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-GEOD-7578, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-TABM-763, E-GEOD-17476, E-TABM-868, E-TABM-601, E-MEXP-1838, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

Growth condition
studied in E-GEOD-13073, E-MEXP-2657, E-GEOD-12773, E-TABM-127, E-GEOD-9764, ... (8 experiments)

Histology
studied in E-TABM-234, E-GEOD-16194, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-TABM-666, E-MEXP-1648, ... (18 experiments)

Infection
studied in E-GEOD-12108

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-GEOD-9171

Media
studied in E-MEXP-765

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-26495, E-GEOD-19703, E-GEOD-1657, E-GEOD-17636, ... (6 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-19445, E-GEOD-19246

RNAi
studied in E-MEXP-2115, E-MEXP-1857, E-MEXP-1315

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-12198

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4271, E-GEOD-4922

Processing time: 0.391 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM